Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avidity Biosciences ( (RNA) ) has issued an update.
Following the closing of a previously agreed merger, Avidity Biosciences terminated its equity incentive plans, employee stock purchase plan and an August 9, 2024 sales agreement with TD Securities, and on February 27, 2026 notified Nasdaq that it had completed the transaction and would delist its common stock. Trading in Avidity shares, already halted the evening of February 26, 2026, is set to be suspended from Nasdaq on March 2, 2026, after which the company plans to deregister its stock and end its SEC reporting obligations, converting each outstanding share into the right to receive merger consideration and eliminating public stockholder rights.
As a result of the merger, Avidity experienced a change in control and became a wholly owned subsidiary of the acquiring parent, with no further change in control arrangements known to the company. The entire board and all executive officers resigned at the effective time and were replaced by the directors and officers of the merger subsidiary, while Avidity’s certificate of incorporation and bylaws were simultaneously amended and restated to mirror those of the merger vehicle, cementing its transition to a privately controlled entity.
The most recent analyst rating on (RNA) stock is a Hold with a $78.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.
Spark’s Take on RNA Stock
According to Spark, TipRanks’ AI Analyst, RNA is a Neutral.
The score is driven primarily by mixed financial fundamentals—strong balance sheet but heavy, accelerating losses and cash burn—tempered by solid technical trend support and positive merger/spin-off progress. Valuation remains pressured by negative earnings and no dividend.
To see Spark’s full report on RNA stock, click here.
More about Avidity Biosciences
Avidity Biosciences operates in the biopharmaceutical industry, focusing on the development of RNA-based therapies. The company’s common stock has been listed on the Nasdaq Global Select Market, giving it access to public equity investors prior to the completion of the merger described in recent filings.
Average Trading Volume: 2,461,292
Technical Sentiment Signal: Buy
Current Market Cap: $11.29B
For detailed information about RNA stock, go to TipRanks’ Stock Analysis page.